These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 11837555

  • 1. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population.
    Pathak DS, Davis EA, Stanford RH.
    Pharmacotherapy; 2002 Feb; 22(2):166-74. PubMed ID: 11837555
    [Abstract] [Full Text] [Related]

  • 2. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy.
    Bukstein DA, Henk HJ, Luskin AT.
    Clin Ther; 2001 Sep; 23(9):1589-600. PubMed ID: 11589270
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast.
    Stempel DA, Mauskopf J, McLaughlin T, Yazdani C, Stanford RH.
    Respir Med; 2001 Mar; 95(3):227-34. PubMed ID: 11266241
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
    Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P.
    Pharmacoeconomics; 2002 Mar; 20(13):909-18. PubMed ID: 12381242
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline.
    Allen-Ramey FC, Duong PT, Riedel AA, Markson LE, Weiss KB.
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):373-80. PubMed ID: 15521374
    [Abstract] [Full Text] [Related]

  • 10. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.
    Balkrishnan R, Nelsen LM, Kulkarni AS, Pleasants RA, Whitmire JT, Schechter MS.
    J Asthma; 2005 Feb; 42(1):35-40. PubMed ID: 15801326
    [Abstract] [Full Text] [Related]

  • 11. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
    Pieters WR, Wilson KK, Smith HC, Tamminga JJ, Sondhi S.
    Treat Respir Med; 2005 Feb; 4(2):129-38. PubMed ID: 15813665
    [Abstract] [Full Text] [Related]

  • 12. Pharmacoeconomic studies of asthma controller drugs: marketing gimmick or icing on the cake?
    Hendeles L, Segal R.
    Pharmacotherapy; 2002 Feb; 22(2):131-3. PubMed ID: 11837550
    [No Abstract] [Full Text] [Related]

  • 13. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.
    Busse W, Wolfe J, Storms W, Srebro S, Edwards L, Johnson M, Bowers BW, Rogenes PR, Rickard K.
    J Fam Pract; 2001 Jul; 50(7):595-602. PubMed ID: 11485708
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis.
    Armstrong EP, Malone DC.
    Pharmacotherapy; 2002 Sep; 22(9):1117-23. PubMed ID: 12222547
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma.
    Stempel DA, Meyer JW, Stanford RH, Yancey SW.
    J Allergy Clin Immunol; 2001 Jan; 107(1):94-8. PubMed ID: 11149997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.